BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simbrunner B, Trauner M, Reiberger T. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. Aliment Pharmacol Ther 2021;54:1243-62. [PMID: 34555862 DOI: 10.1111/apt.16602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou S, You H, Qiu S, Yu D, Bai Y, He J, Cao H, Che Q, Guo J, Su Z. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR). Biomed Pharmacother 2022;154:113577. [PMID: 35988420 DOI: 10.1016/j.biopha.2022.113577] [Reference Citation Analysis]
2 Ni Y, Lu M, Xu Y, Wang Q, Gu X, Li Y, Zhuang T, Xia C, Zhang T, Gou X, Zhou M. The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease. Front Microbiol 2022;13:908011. [DOI: 10.3389/fmicb.2022.908011] [Reference Citation Analysis]
3 Panzitt K, Zollner G, Marschall H, Wagner M. Recent advances on FXR-targeting therapeutics. Molecular and Cellular Endocrinology 2022. [DOI: 10.1016/j.mce.2022.111678] [Reference Citation Analysis]
4 Thibaut MM, Bindels LB. Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation. Trends in Molecular Medicine 2022. [DOI: 10.1016/j.molmed.2021.12.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]